期刊文献+

化疗诱发异基因造血干细胞移植后急性T淋巴细胞白血病复发患者移植物抗宿主病及其Th17/Treg细胞动态观察

Dynamic observation of GVHD induced by chemotherapy and Th17/Treg in a relapse T-ALL patient after allo-HSCT
原文传递
导出
摘要 目的探讨化疗诱发异基因造血干细胞移植(allo—HSCT)后急性T淋巴细胞白血病(T—ALL)髓外复发患者发生移植物抗宿主病(GVHD)的临床特征及Thl7/Treg细胞及相关细胞因子的动态变化。方法以20名健康体检者为健康对照。1例诊断为T—ALL患者在2个疗程化疗后血液学完全缓解时,行同胞供者HLA配型全相合的allo—HSCT。移植后对患者进行随访,同时采用流式细胞术和酶联免疫吸附法(ELISA)检测患者在供者细胞植入状态、疾病复发、GVHD各个时期外周血TM7/Treg细胞及相关因子的动态变化。结果患者+27天获得完全供者嵌合体(FDC),+34天造血功能完全恢复,+110天出现慢性GVHD(cGVHD),+264天在cGVHD状态下髓外复发,Hyper.CVAD方案化疗后,+347天相继出现表现为口腔溃疡的cGVHD及伴有Ⅳ度肠道GVHD的重叠综合征。患者外周血中Thl7细胞占cD:T细胞比例在发生重叠综合征时(1.70%)较健康对照组[(0.56±0.35)%】有所增高,Treg细胞占cDjT细胞的比例在患者发生cGVHD时(4.66%)较健康对照组【(0.59±0.33)%】及患者复发时(0.39%)、造血干细胞植入时(1.15%)高,发生重叠综合征时升高更加明显(7.83%),同时在复发时Thl7/Treg比例〉1,而发生GVHD时Thl7/Treg比例〈1。血清中白细胞介素。17A在患者发生cGVHD时(6.11Pg/m1)及化疗后诱导重叠综合征时(6.81Pg/m1)均较健康对照组【(5.19±0.77)Pg/m1]有所增高,TGF—β1浓度在患者移植后不同时期均较健康对照[(48.81±4.90)ng/ml】高。结论化疗可诱发allo—HSCT术后复发的急性白血病患者发生GVHD;Thl7/Treg细胞及相关细胞因子的失衡可能与疾病复发、GVHD的发生相关。 Objective To explore clinical features of chemotherapy-induced graft-versus-host disease and to observe the dynamical changes of Thl7/Treg ratio and related eytokines in one relapsed acute T- lymphohlastic leukemia after allo-HSCT. Methods Twenty health volunteers were heahhy controls. One patient achieved complete haematologie remission after two courses of chemotherapy and underwent matched HLA identical sibling allogenic peripheral blood stem cell transplantation, donor cell implanted state, disease recurrence and graft- versus -host disease were observed and Thl7/Treg cells and its related factors in the peripheral blood were detected in different periods dynamically changes by methods of flow cytometry and ELISA. Results The patient achieved complete donor chimerism (FDC) at day +27 after transplantation. Hernatopoietic function was fully recovered at day +34.Chronic GVHD (cGVHD) occurred at day +110. Thereafter, extramedullary relapse occurred in cGVHD state at day +264. After one course of Hyper-CVAD chemotherapy, patient complicated overlap syndrome with eGVHD of oral cavity ulcer and degree IV intestinal aGVHD at day +294 and day +347, respectively. Thl7 cell ratio in CD T cells (l.7 %) in the overlap syndrome slightly increased,compared with control group [(0.56±0.35) %]. The ratio of Treg cells in CD T cells (4.66 %) with cGVHD increased compared with normal control group [(0.59±0.33) %], recurrence (0.39 %), and hematopoietic stem cell implantation (1.15 %), but the ratio of Treg cells increased significantly when patient complicated overlap syndrome (7.83 %). The ratios of Thl7/Treg were more than 1 at relapse and less than 1 at GVHD stage. The IL-17A level in serum significantly increased in cGVHD (6.114 pg/ml) and overlap syndrome (6.805 pg/m|) stage compared with normal control group [(5.19±0.77) pg/ml]. TGF-β1 levels were significantly higher at different periods after transplantation compared with control group [(48.81± 4.9) ng/ml]. Conclusion Chemotherapy can induce GVHD in relapsed acute leukemia patients after hematopoietic stem cell transplantation, and the imbalance of the Thl7/Treg cells and its cytokines maybe related with disease relapse and GVHD.
出处 《白血病.淋巴瘤》 CAS 2012年第11期663-667,共5页 Journal of Leukemia & Lymphoma
基金 广东省科技攻关项目(2011B031800053),广州市科技攻关项目(2011Y1-00038-3)
关键词 白血病 淋巴细胞 急性 造血干细胞移植 移植物抗宿主病 Th17细胞 TREG 细胞 Leukemia, lymphoblastic, acute Hematopoietic stem cell transplantation Graft vs host disease Th17 cells Treg cells
  • 相关文献

参考文献5

二级参考文献45

  • 1Kimura A, Kishimoto T. IL-6: Regulator of Treg/Th17 balance [J]. Eur J Immunol, 2010, 40(7) : 1830-1835.
  • 2Zhou L, Lopes JE, Chong MM, et al. TGF-beta-induced Foxp3 inhibits T(H) 17 cell differentiation by antagonizing ROR gamma T function [J]. Nature, 2008, 453(7192): 236-240.
  • 3BetteUi E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector Th17 and regulatory T cells [J]. Nature, 2006, 441(7090) : 235-238.
  • 4Bettelli E, Korn T, Kuchroo VK. Th17: The third member of the effector T cell trilogy [ J ]. Curr Opin Immunol, 2007, 19 ( 6 ) : 652-657.
  • 5Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer [ J]. J Clin Invest, 2007, 117 (5) : 1175-1183.
  • 6Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment [J]. J Immunol, 2007, 178(11) : 6730-6733.
  • 7Voo KS, Wang YH, Santori FR, et al. Identification of IL-17-producing Foxp3^+ regulatory T cells in humans [J]. Proc Natl Acad Sci U S A, 2009, 106(12) : 4793-4798.
  • 8Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J]. Nat Med, 2004, 10(9) : 942-949.
  • 9Ma J, Yu J, Tao X, Cai L, et al. The imbalance between regulatory and IL-17-secreting CD4^+ T cells in lupus patients [ J]. Clin Rheumatol, 2010, 29 ( 11 ) : 1251-1258.
  • 10Eastaff-Leung N, Mabarrack N, Barbour A, et al. Foxp3^+ regulatory T cells, Thl7 effector cells, and cytokine environment in inflammatory bowel disease [ J]. J Clin Immunol, 2010, 30( 1 ): 80-89.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部